194 related articles for article (PubMed ID: 19250676)
1. Extramedullary (EMP) relapse in unusual locations in multiple myeloma: Is there an association with precedent thalidomide administration and a correlation of special biological features with treatment and outcome?
Katodritou E; Gastari V; Verrou E; Hadjiaggelidou C; Varthaliti M; Georgiadou S; Laschos K; Xirou P; Yiannaki E; Constantinou N; Markala D; Zervas K
Leuk Res; 2009 Aug; 33(8):1137-40. PubMed ID: 19250676
[TBL] [Abstract][Full Text] [Related]
2. [Low-dose thalidomide in refractory and relapsing multiple myeloma].
Radocha J; Maisnar V
Vnitr Lek; 2007 Feb; 53(2):129-34. PubMed ID: 17419173
[TBL] [Abstract][Full Text] [Related]
3. Thromboembolism in patients on thalidomide for myeloma.
Bowcock SJ; Rassam SM; Ward SM; Turner JT; Laffan M
Hematology; 2002 Feb; 7(1):51-3. PubMed ID: 12171777
[TBL] [Abstract][Full Text] [Related]
4. Unusual cutaneous involvement during plasma cell leukaemia phase in a multiple myeloma patient after treatment with thalidomide: a case report and review of the literature.
Alexandrescu DT; Koulova L; Wiernik PH
Clin Exp Dermatol; 2005 Jul; 30(4):391-4. PubMed ID: 15953079
[TBL] [Abstract][Full Text] [Related]
5. Monotherapy with low-dose thalidomide for relapsed or refractory multiple myeloma: better response rate with earlier treatment.
Maisnar V; Radocha J; Büchler T; Bláha V; Malý J; Hájek R
Eur J Haematol; 2007 Oct; 79(4):305-9. PubMed ID: 17803678
[TBL] [Abstract][Full Text] [Related]
6. Arterial thrombosis with immunomodulatory derivatives in the treatment of multiple myeloma: a single-center case series and review of the literature.
Martin MG; Vij R
Clin Lymphoma Myeloma; 2009 Aug; 9(4):320-3. PubMed ID: 19717384
[TBL] [Abstract][Full Text] [Related]
7. Very low doses of thalidomide as single agent in relapsed/refractory multiple myeloma.
Guglielmelli T; Capella S; Saglio G
Acta Haematol; 2006; 116(1):70-1. PubMed ID: 16809894
[No Abstract] [Full Text] [Related]
8. Single-agent thalidomide induces response in T-cell lymphoma.
Damaj G; Bouabdallah R; Vey N; Bilger K; Mohty M; Gastaut JA
Eur J Haematol; 2005 Feb; 74(2):169-71. PubMed ID: 15654910
[TBL] [Abstract][Full Text] [Related]
9. Arterial and venous thrombotic complications with thalidomide in multiple myeloma.
Alkindi S; Dennison D; Pathare A
Arch Med Res; 2008 Feb; 39(2):257-8. PubMed ID: 18164975
[No Abstract] [Full Text] [Related]
10. Response to thalidomide in multiple myeloma: impact of angiogenic factors.
Rosiñol L; Cibeira MT; Segarra M; Cid MC; Filella X; Aymerich M; Rozman M; Arenillas L; Esteve J; Bladé J; Montserrat E
Cytokine; 2004 May; 26(4):145-8. PubMed ID: 15149630
[TBL] [Abstract][Full Text] [Related]
11. Bradycardia during therapy for multiple myeloma with thalidomide.
Fahdi IE; Gaddam V; Saucedo JF; Kishan CV; Vyas K; Deneke MG; Razek H; Thorn B; Bissett JK; Anaissie EJ; Barlogie B; Mehta JL
Am J Cardiol; 2004 Apr; 93(8):1052-5. PubMed ID: 15081457
[TBL] [Abstract][Full Text] [Related]
12. Thalidomide-dexamethasone versus interferon-alpha-dexamethasone as maintenance treatment after ThaDD induction for multiple myeloma: a prospective, multicentre, randomised study.
Offidani M; Corvatta L; Polloni C; Piersantelli MN; Gentili S; Galieni P; Visani G; Alesiani F; Catarini M; Brunori M; Samori A; Burattini M; Centurioni R; Ferranti M; Giuliodori L; Candela M; Mele A; Marconi M; Leoni P
Br J Haematol; 2009 Mar; 144(5):653-9. PubMed ID: 19036082
[TBL] [Abstract][Full Text] [Related]
13. Leukocytoclastic vasculitis due to thalidomide in multiple myeloma.
Yildirim ND; Ayer M; Küçükkaya RD; Alpay N; Mete O; Yenerel MN; Yavuz AS; Nalçaci M
Jpn J Clin Oncol; 2007 Sep; 37(9):704-7. PubMed ID: 17709605
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of melphalan and prednisone plus thalidomide in patients older than 75 years with newly diagnosed multiple myeloma: IFM 01/01 trial.
Hulin C; Facon T; Rodon P; Pegourie B; Benboubker L; Doyen C; Dib M; Guillerm G; Salles B; Eschard JP; Lenain P; Casassus P; Azaïs I; Decaux O; Garderet L; Mathiot C; Fontan J; Lafon I; Virion JM; Moreau P
J Clin Oncol; 2009 Aug; 27(22):3664-70. PubMed ID: 19451428
[TBL] [Abstract][Full Text] [Related]
15. Deep vein thrombosis occurring on treatment of patients receiving thalidomide with erythropoietin.
Chennuru S; Baumann MA
Intern Med J; 2007 Jul; 37(7):506-7. PubMed ID: 17547733
[No Abstract] [Full Text] [Related]
16. Emerging combination treatment strategies containing novel agents in newly diagnosed multiple myeloma.
Lonial S; Cavenagh J
Br J Haematol; 2009 Jun; 145(6):681-708. PubMed ID: 19344388
[TBL] [Abstract][Full Text] [Related]
17. Thalidomide in elderly patients with multiple myeloma.
Kusumi E; Matsumura T; Yuji K; Tanaka Y; Kami M
Lancet; 2006 Jun; 367(9527):1977; author reply 1977-8. PubMed ID: 16782479
[No Abstract] [Full Text] [Related]
18. Thalidomide in multiple myeloma: state of art.
Tosi P; Cavo M
Haematologica; 2002 Mar; 87(3):233-4. PubMed ID: 11869932
[No Abstract] [Full Text] [Related]
19. Desensitization to thalidomide in a patient with multiple myeloma.
Nucera E; Schiavino D; Hohaus S; Leone G; Buonomo A; Lombardo C; Patriarca G
Clin Lymphoma Myeloma; 2008 Jun; 8(3):176-8. PubMed ID: 18650182
[TBL] [Abstract][Full Text] [Related]
20. Thalidomide therapy and deep venous thrombosis in multiple myeloma.
Rajkumar SV
Mayo Clin Proc; 2005 Dec; 80(12):1549-51. PubMed ID: 16350272
[No Abstract] [Full Text] [Related]
[Next] [New Search]